TX-PHILLIPS-66
19.7.2022 15:02:13 CEST | Business Wire | Pressemeddelelse
Phillips 66 (NYSE: PSX) og H2 Energy Europe ("H2 Energy") meddelte i dag, at de har indgået en 50-50 joint venture-aftale med henblik på etablering og drift af et netværk af brinttankstationer og skabelsen af et grønt brintøkosystem i Tyskland, Østrig og Danmark.
JET H2 Energy Austria GmbH (JET H2 Energy), som udgør joint venture-aftalen mellem datterselskaberne Phillips 66 Limited og H2 Energy Europe SA, forener Phillips 66's store ekspertise inden for detailhandel med H2 Energys erfaringer og ekspertise inden for brint. JET H2 Energy bliver en central aktør i branchen og vil sætte skub i udviklingen af brint som brændstof i Europa. Det nye selskab planlægger at etablere cirka 250 brinttankstationer inden 2026.
"Det er vores mål at gøre brint til en førende energibærer inden for emissionsfri mobilitet. Vi vil skabe ligevægt i de involverede aktørers interesser i hele brintværdikæden og skabe et bæredygtigt brintøkosystem,” udtaler Olaf Borbor, administrerende direktør for JET H2 Energy.
"Phillips 66 er med stor succes til stede på detailmarkedet i Europa med sit brand JET® . H2 Energy har en dokumenteret track record inden for skabelsen af et vellykket grønt brintøkosystem i Schweiz. Parternes kompetencer supplerer derfor hinanden ideelt i den næste fase i udviklingen af brintøkonomien."
JET H2 Energy vil søge og udvælge steder (greenfield-udvikling, JET® og kundesteder), etablere og drive brinttankstationer til både tunge og lette køretøjer og personbiler (FCEV'er), forsyne brinttankstationerne med grøn brint og opbygge relationer med kunder og originaludstyrsproducenter.
JET H2 Energy vil drage fordel af sit tætte samarbejde med Hyundai Hydrogen Mobility, der er eksklusiv europæisk forhandler af Hyundai Xcient-brintbrændselscellelastbilen.
Ledelsesteamet består af Olaf Borbor (CEO), Markus Wolf (CFO) og Jonas Erdmann (Commercial Manager). Det tyske hovedkvarter er baseret i Hamborg.
Phillips 66 Limited er en kombineret energiproduktions- og logistikvirksomhed hjemhørende i Storbritannien. Virksomheden er et datterselskab under og 100 % ejet af Phillips 66. Phillips 66 har med flere end 1.000 JET® -stationer en stærk tilstedeværelse på markedet i Europa og via joint venture-samarbejdet Coop Mineraloel AG et voksende netværk til optankning af brint i Schweiz.
H2 Energy Europe med hovedsæde i Schweiz er et joint venture mellem selskabet Trafigura Pte Ltd., der handler med råvarer, og H2 Energy Holding AG, en førende brintleverandør i Europa med investeringer i produktion, distribution og anvendelse af grøn brint. H2 Energy var gennem sine tilknyttede selskaber den første til at udvikle og levere brintbrændselscellelastbiler til kommercielle brugere og skabe et grønt brintbrændstof-økosystem i Schweiz.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220718005806/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum